Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression.

Phenylpropanolamine (PPA) is an appetite suppressant. Repeated treatment with PPA can decrease food intake on initial days, but on subsequent days, food intake gradually returns to normal (tolerant effect). In an attempt to investigate the underlying mechanisms of PPA tolerance, the authors examined the roles of catecholamine (CAT) and hypothalamic neuropeptide Y (NPY) genome. Results revealed that pretreatment with either bupropion, a CAT transporter inhibitor, or a-methylparatyrosine, a tyrosine hydroxylase inhibitor, modulated the effect of PPA tolerance. Moreover, results also revealed that the alteration in NPY messenger RNA level coincided with the change of feeding behavior during PPA treatment and that infusions of NPY antisense oligonucleotide into the cerebroventricle abolished the effect of PPA tolerance. These findings suggest that cerebral CAT and hypothalamic NPY genome are involved in the development of tolerance to PPA-induced appetite suppression.

[1]  M. Cowley,et al.  Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice , 2007, Neuropsychopharmacology.

[2]  Antonio Alcaro,et al.  Dopamine β-Hydroxylase Knockout Mice have Alterations in Dopamine Signaling and are Hypersensitive to Cocaine , 2006, Neuropsychopharmacology.

[3]  P. Vallet,et al.  Increased Infarct Size and Lack of Hyperphagic Response after Focal Cerebral Ischemia in Peroxisome Proliferator-Activated Receptor β-Deficient Mice , 2006, Journal of Cerebral Blood Flow and Metabolism.

[4]  A. Tanács,et al.  Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. , 2005, Journal of affective disorders.

[5]  Lijun Li,et al.  Chronic Stress Induces Rapid Occlusion of Angioplasty-Injured Rat Carotid Artery by Activating Neuropeptide Y and Its Y1 Receptors , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[6]  M. Morris,et al.  Early dietary intervention: long-term effects on blood pressure, brain neuropeptide Y, and adiposity markers. , 2005, American journal of physiology. Endocrinology and metabolism.

[7]  N. Subhedar,et al.  Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats , 2005, Brain Research.

[8]  A. Grace,et al.  Dopamine modulates excitability of basolateral amygdala neurons in vitro. , 2005, Journal of neurophysiology.

[9]  D. Morilak,et al.  Norepinephrine Release in Medial Amygdala Facilitates Activation of the Hypothalamic‐Pituitary‐Adrenal Axis in Response to Acute Immobilisation Stress , 2005, Journal of neuroendocrinology.

[10]  Shun-Fa Yang,et al.  Immunohistochemical and genomic evidence for the involvement of hypothalamic neuropeptide Y (NPY) in phenylpropranolamine-mediated appetite suppression , 2004, Peptides.

[11]  R. Palmiter,et al.  Dysregulation of Striatal Dopamine Signaling by Amphetamine Inhibits Feeding by Hungry Mice , 2004, Neuron.

[12]  T. Bolwig,et al.  Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation , 2004, Journal of neuroscience research.

[13]  S. Kalra,et al.  NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy , 2004, Neuropeptides.

[14]  L. Delbridge,et al.  Vascular and brain neuropeptide Y in banded and spontaneously hypertensive rats , 2004, Peptides.

[15]  J. R. Maximino,et al.  Change in the expression of NPY receptor subtypes Y1 and Y2 in central and peripheral neurons related to the control of blood pressure in rats following experimental hypertension , 2004, Neuropeptides.

[16]  N. Deiorio.  Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication. , 2004 .

[17]  D. Kuo.  Further evidence for the mediation of both subtypes of dopamine D1/D2 receptors and cerebral neuropeptide Y (NPY) in amphetamine-induced appetite suppression , 2003, Behavioural Brain Research.

[18]  Sheng Bi,et al.  Acute food deprivation and chronic food restriction differentially affect hypothalamic NPY mRNA expression. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[19]  Juei-Tang Cheng,et al.  Both α1-adrenergic and D1-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice , 2003, Neuroscience Letters.

[20]  L. Dwoskin,et al.  Effect of bupropion on nicotine self-administration in rats , 2003, Psychopharmacology.

[21]  Lijun Li,et al.  Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? , 2003, Canadian journal of physiology and pharmacology.

[22]  F. Svec,et al.  The Effects of Phenylpropanolamine on Zucker Rats Selected for Fat Food Preference , 2003, Nutritional neuroscience.

[23]  A. Inui,et al.  Effect of amphetamine repeated treatment on the feeding behavior in neuropeptide Y-overexpressing mice , 2002, Neuroscience Letters.

[24]  Juei-Tang Cheng,et al.  Role of cerebral dopamine but not plasma insulin, leptin and glucocorticoid in the development of tolerance to the anorectic effect of amphetamine , 2002, Neuroscience Research.

[25]  M. Fuller,et al.  Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. , 2002, The Journal of clinical psychiatry.

[26]  J. Cheng,et al.  Role of hypothalamic neuropeptide Y (NPY) in the change of feeding behavior induced by repeated treatment of amphetamine. , 2001, Life sciences.

[27]  A. Buist,et al.  Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation , 2001, Annals of Internal Medicine.

[28]  U. McCann,et al.  Evidence against an essential role of endogenous brain dopamine in methamphetamine‐induced dopaminergic neurotoxicity , 2001, Journal of neurochemistry.

[29]  T. Mersfelder.  Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. , 2001, Cleveland Clinic journal of medicine.

[30]  B. Spring,et al.  Weight suppression and weight rebound in ex-smokers treated with fluoxetine. , 1999, Journal of consulting and clinical psychology.

[31]  S. Woods,et al.  Signals that regulate food intake and energy homeostasis. , 1998, Science.

[32]  S. Honma,et al.  Methamphetamine stimulates the release of neuropeptide Y and noradrenaline from the paraventricular nucleus in rats , 1996, Brain Research.

[33]  Roy J Martin,et al.  ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release , 1995, Regulatory Peptides.

[34]  R. Klesges,et al.  Effects of phenylpropanolamine on withdrawal symptoms , 1995, Psychopharmacology.

[35]  A. Levine,et al.  Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. , 1994, The American journal of physiology.

[36]  J. C. Amos,et al.  Effects of chronic phenylpropanolamine infusion and termination on body weight, food consumption and water consumption in rats , 1994, Psychopharmacology.

[37]  B. Stanley,et al.  Evidence that neuropeptide Y and dopamine in the perifornical hypothalamus interact antagonistically in the control of food intake , 1993, Brain Research.

[38]  H. McCarthy,et al.  Intense exercise and food restriction cause similar hypothalamic neuropeptide Y increases in rats. , 1993, The American journal of physiology.

[39]  Schteingart De.  Effectiveness of phenylpropanolamine in the management of moderate obesity. , 1992 .

[40]  B. T. Davies,et al.  Reversal of cirazoline- and phenylpropanolamine-induced anorexia by the α 1-receptor antagonist prazosin , 1992, Pharmacology Biochemistry and Behavior.

[41]  R. Klesges,et al.  The effects of phenylpropanolamine on dietary intake, physical activity, and body weight after smoking cessation , 1990, Clinical pharmacology and therapeutics.

[42]  B. Morris.  Neuronal localisation of neuropeptide Y gene expression in rat brain , 1989, The Journal of comparative neurology.

[43]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[44]  T. Maher,et al.  Adrenergic receptor subtype activation by (+)‐, (−)‐ and (±)‐norephedrine in the pithed rat , 1987, The Journal of pharmacy and pharmacology.

[45]  P. Emson,et al.  Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system—II. Immunohistochemical analysis , 1986, Neuroscience.

[46]  T. L. Sellers,et al.  Weight loss induced by chronic phenylpropanolamine: Anorexia and brown adipose tissue thermogenesis , 1986, Pharmacology Biochemistry and Behavior.

[47]  T. O'donohue,et al.  The anatomy of neuropeptide-y-containing neurons in rat brain , 1985, Neuroscience.

[48]  V. Klimek,et al.  Central effects of repeated treatment with bupropion. , 1985, Polish journal of pharmacology and pharmacy.

[49]  R. Ritter,et al.  Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. , 1981, Science.

[50]  S. Leibowitz,et al.  Pharmacological characterization of perifornical hypothalamic dopamine receptors mediating feeding inhibition in the rat , 1979, Brain Research.

[51]  K. Johnson,et al.  A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. , 2005, Addictive behaviors.

[52]  B. Hoebel,et al.  Similarities between the stimulus properties of phenylpropanolamine and amphetamine , 2004, Psychopharmacology.

[53]  B. Jeanrenaud,et al.  Effects of neuropeptides and leptin on nutrient partitioning: dysregulations in obesity. , 2001, Annual review of medicine.

[54]  D. Schteingart.  Effectiveness of phenylpropanolamine in the management of moderate obesity. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[55]  M. Zarrindast,et al.  Anorectic and behavioural effects of bupropion. , 1988, General pharmacology.

[56]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .